Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized…
By M. Ellis, A. Coop, Baljit Singh, L. Mauriac, Antonio Llombert-Cussac, F. Jänicke, William Miller, D. Evans, M. Dugan, C. Brady and 2 more. Journal of Clinical Oncology, 2001
1,094 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Oncology
View Paper: https://www.semanticscholar.org/paper/3c997ff5bea00468698891e11512407f9f182ff0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Genetics
In Oncology
Citations in the corpus
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. (2004, background): “Tamoxifen is thought to act 1998; Ellis et al., 2001; Goss et al., 2003), chemotherapeutic agents (Colleoni et al., 2003a), or inhibitors of other signaling pathways, primarily as a competitive inhibitor of estrogen binding to estrogen receptor (ER), and it has no effect on tumor cells lacking such…”
- American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (2006, background): “Although controversial, preclinical and clinical studies have suggested that this effect may be specific to selective estrogen receptor modulator therapy, such as tamoxifen, and perhaps not to estrogen depletion therapies, such as with aromatase inhibitors.(8) HER2 status also appears to be predicti”
- Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer (2003, background): “This trial also suggested that the effects of HER on ER requires oestrogenic activation, since the effect of HER1/2 overexpression on survival was absent in patients treated with an aromatase inhibitor [66].”